BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,250 shares of the company’s stock after buying an additional 17,481 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned 0.07% of IDEXX Laboratories worth $14,003,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC purchased a new position in IDEXX Laboratories during the first quarter worth $105,000. Three Peaks Capital Management LLC purchased a new position in IDEXX Laboratories during the first quarter worth $108,000. Optimum Investment Advisors purchased a new position in IDEXX Laboratories during the first quarter worth $139,000. Cerebellum GP LLC purchased a new position in IDEXX Laboratories during the second quarter worth $181,000. Finally, Financial Gravity Wealth Inc. purchased a new position in IDEXX Laboratories during the first quarter worth $191,000. 91.19% of the stock is owned by institutional investors.

Shares of IDXX opened at $251.70 on Wednesday. The firm has a market cap of $21.60 billion, a PE ratio of 76.74, a P/E/G ratio of 2.28 and a beta of 0.69. IDEXX Laboratories, Inc. has a 12-month low of $146.09 and a 12-month high of $255.09. The company has a quick ratio of 0.73, a current ratio of 0.96 and a debt-to-equity ratio of -14.77.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, August 1st. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.17 by $0.06. The firm had revenue of $580.75 million during the quarter, compared to analyst estimates of $574.68 million. IDEXX Laboratories had a net margin of 14.50% and a negative return on equity of 703.80%. The business’s revenue was up 14.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 earnings per share. analysts predict that IDEXX Laboratories, Inc. will post 4.18 EPS for the current year.

IDXX has been the subject of several recent analyst reports. ValuEngine raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Stifel Nicolaus lifted their price objective on shares of IDEXX Laboratories from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, May 7th. Canaccord Genuity reaffirmed a “positive” rating and set a $215.00 price objective on shares of IDEXX Laboratories in a research note on Monday, May 7th. BidaskClub lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 9th. Finally, Zacks Investment Research lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, May 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. IDEXX Laboratories presently has an average rating of “Buy” and an average target price of $244.00.

In other news, insider Michael Lane sold 5,912 shares of the business’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $243.78, for a total transaction of $1,441,227.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce L. Claflin bought 415 shares of the stock in a transaction dated Friday, August 3rd. The shares were bought at an average cost of $242.12 per share, with a total value of $100,479.80. Following the completion of the purchase, the director now directly owns 1,415 shares of the company’s stock, valued at approximately $342,599.80. The disclosure for this purchase can be found here. Insiders have sold 70,129 shares of company stock valued at $17,159,219 over the last three months. Insiders own 2.56% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.